Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthy Living Arizona.
Press releases published on September 25, 2025
A Breakthrough Approach to Hypnosis in Phoenix, Puts Clients First by Making Every Session Unique
PHOENIX, AZ, UNITED STATES, September 25, 2025 /EINPresswire.com/ -- In the world of mental health and wellness, one-size-fits-all approaches are still surprisingly common. Studies show that nearly 65.9% of hypnotists rely on scripts, delivering the same …
SDC Launches SDC Insights with Sidekick™ — Ushering in a New Era of AI-Native Clinical Trial Oversight
Built as an AI-native platform, SDC Insights with Sidekick delivers predictive, transparent, transformative oversight — the future of clinical research today. TEMPE, AZ, UNITED STATES, September 25, 2025 /EINPresswire.com/ -- SDC Clinical, a leader in …
Lytus Technologies Holdings PTV. Ltd. Announces 1-for-2,500 Reverse Stock Split
Dubai, United Arab Emirates, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Lytus Technologies Holdings PTV. Ltd. (OTCQB: LYTHF) (the “Company”), a leader in platform services and next-generation technology, today announced that it intends to effect a reverse stock …
Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly
Novel nonpeptide SST2 agonist PALSONIFY advances the treatment paradigm as the first once-daily, oral therapy approved by the FDA to treat acromegaly Approval based on data from two pivotal Phase 3 trials where PALSONIFY was well tolerated and resulted in …
Medirom Decides to Double Installation of Authentication Device “Orb” to 200 Stores, in Collaboration with “World” Co-founded by Sam Altman and Alex Blania
TOKYO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (Headquarters: Minato-ku, Tokyo; CEO: Kouji Eguchi; NASDAQ: MRM), a diversified healthcare company, has joined “World,” a “proof of human” protocol co-founded by Sam Altman and …
Kura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomenib Data in Relapsed/Refractory NPM1-Mutated AML in the Journal of Clinical Oncology
– KOMET-001 in R/R NPM1-m AML met its primary endpoint with ziftomenib monotherapy demonstrating significant clinical benefit and deep responses – – Consistent activity across pre-specified subgroups, regardless of prior HSCT, prior venetoclax, lines of …
Medicenna Announces Results of Annual Meeting of Shareholders
TORONTO and HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced the voting …
Organogenesis Provides Update on Second Phase 3 ReNu® Study
Company maintains confidence in ReNu as innovative pain management therapy Second Phase 3 trial demonstrates numerical improvement in baseline pain reduction over the first Phase 3 trial despite not meeting the primary endpoint Statistically significant …
Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025
TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter 2025 financial results on Wednesday, November 5, 2025, at 7:00 a.m. ET. …
Buying Guide 2025- most effective female libido booster pills in 2025 By OhYes
Washington Dc, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Oh Yes, a leading name in women’s sexual wellness, is proud to introduce its latest breakthrough in female libido enhancement — a scientifically formulated supplement designed to reignite desire, amplify …
Medtimo Files Patent Infringement Complaint Against Allurion Technologies
Complaint Seeks to Protect Medtimo’s Balloon System Technology and Alleges That Allurion Infringes Three Medtimo Patents IRVINE, Calif., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Medtimo Inc, a wholly owned subsidiary of Biorad Medisys Private Limited, offering …
LifeMD to Participate in the ROTH 4th Annual Healthcare Opportunities Conference
NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced its participation in the ROTH 4th Annual Healthcare Opportunities Conference, which will be held October 9, 2025 …
Option Care Health to Announce Third Quarter 2025 Financial Results and Host Conference Call
BANNOCKBURN, Ill., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Option Care Health Inc. (“Option Care Health”) (NASDAQ: OPCH), the nation’s largest independent provider of home and alternate site infusion services, today announced that the company will release …
CapsoVision to Participate in the 4th Annual ROTH Healthcare Opportunities Conference
SARATOGA, Calif., Sept. 25, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that Johnny Wang, President and Chief …
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIAMI, Sept. 25, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD’s Board …
Harrow Launches Harrow Access for All (HAFA)
HAFA to Expand Harrow’s Innovative Market Access Model Across Ophthalmic Portfolio Program will be available in late 2025 through the HarrowAccess.com Portal NASHVILLE, Tenn., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of …
Xenon Announces Upcoming Investor Webinar to Discuss Early-Stage Ion Channel Programs for the Potential Treatment of Pain
VANCOUVER, British Columbia and BOSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing …
Cidara Therapeutics Announces First Participants Dosed in Phase 3 ANCHOR Trial Evaluating CD388 for the Prevention of Seasonal Influenza in High-Risk Populations
- Phase 3 study expected to enroll 6,000 participants starting in the Northern Hemisphere - Participants will include adults over 65 years of age in addition to individuals with high-risk co-morbidities and immune compromised status SAN DIEGO, Sept. 25, …
Buying Guide 2025- Pills to Increase Sex Drive Female 2025 -Start Your Libido Life Today with Oh yes
washington DC, Sept. 25, 2025 (GLOBE NEWSWIRE) -- In 2025, women’s sexual wellness takes center stage. OhYesBashed proudly announces the launch of its definitive Buying Guide 2025 – Pills to Increase Sex Drive for Women, a breakthrough resource designed to …